Different DNA methylome, transcriptome and histological features in uterine fibroids with and without MED12 mutations

Ryo Maekawa*, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Shun Sato, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Tetsuro Tamehisa, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Takahiro Sakai, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Takuya Kajimura, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Kotaro Sueoka, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Norihiro Sugino, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Ube, 755-8505 Japan

Supponental Tuble 510. Included DTUT metalytation and initial expression reversion of the of the office of the and the office of									
	MED12m-positive uterine fibroids $(n = 9)$	MED12m-negative uterine fibroids $(n = 12)$	Total						
DNA methylation (15% c	or more DNA methylation level than myometrium	m)							
SATB2	88.9% (8/9)	75% (9/12)	81% (17/21)						
NRG1	100% (9/9)	75% (9/12)	85.7% (18/21)						
mRNA expression (2-fold	d or more mRNA expression level than myomet	rium)							
SATB2	100% (9/9)	75% (9/12)	85.7 % (18/21)						
NRG1	100% (9/9)	66.7% (8/12)	81.0 % (17/21)						
	~ /								

Supple	emental Table S	10. Increased D	NA methyl	lation and mRNA	A expression	levels of	i SATB2 c	or NRG1 ir	n uterine	fibroids	with and y	without MED	12 mutations.
11			2		1								